Arcturus Therapeutics Holdings Inc. (ARCT)
Largest Insider Buys in Sector
ARCT Stock Price History Chart
ARCT Stock Performance
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Insider Activity of Arcturus Therapeutics Holdings Inc.
Over the last 12 months, insiders at Arcturus Therapeutics Holdings Inc. have bought $0 and sold $5.37M worth of Arcturus Therapeutics Holdings Inc. stock.
On average, over the past 5 years, insiders at Arcturus Therapeutics Holdings Inc. have bought $518,735 and sold $34.56M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,222 shares for transaction amount of $39,996 was made by Marquet Magda (director) on 2022‑12‑15.
List of Insider Buy and Sell Transactions, Arcturus Therapeutics Holdings Inc.
| 2024-06-12 | Sale | SASSINE ANDY | Chief Financial Officer | 50,000 0.1838% | $32.03 | $1.6M | -11.82% | |
| 2024-06-05 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 114 0.0004% | $45.00 | $5,130 | -30.20% | |
| 2024-06-03 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 26,000 0.095% | $40.01 | $1.04M | -23.67% | |
| 2024-03-25 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 17,435 0.0652% | $35.02 | $610,574 | -12.61% | |
| 2024-03-19 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 8,565 0.033% | $35.01 | $299,839 | -9.66% | |
| 2023-11-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0187% | $18.72 | $93,602 | +68.99% | |
| 2023-10-02 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0188% | $25.61 | $128,062 | +20.81% | |
| 2023-09-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0187% | $31.45 | $157,264 | -4.13% | |
| 2023-08-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0184% | $34.91 | $174,550 | -12.59% | |
| 2023-07-14 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 25,000 0.093% | $35.01 | $875,250 | -12.53% | |
| 2023-07-14 | Sale | Kummerfeld Keith C | See Remarks | 6,968 0.0259% | $35.00 | $243,880 | -12.53% | |
| 2023-07-03 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0189% | $28.75 | $143,750 | +8.13% | |
| 2023-06-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0189% | $27.16 | $135,800 | +10.95% | |
| 2023-05-11 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 7,925 0.0279% | $30.24 | $239,652 | -9.63% | |
| 2023-05-10 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 17,075 0.0656% | $30.00 | $512,250 | -0.37% | |
| 2023-05-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0187% | $25.93 | $129,650 | +12.25% | |
| 2023-04-18 | Sale | Kummerfeld Keith C | See Remarks | 6,968 0.0265% | $28.18 | $196,358 | +5.17% | |
| 2023-04-03 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0186% | $25.38 | $126,900 | +11.48% | |
| 2023-03-06 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0191% | $16.07 | $80,350 | +75.95% | |
| 2022-12-15 | Marquet Magda | director | 2,222 0.0083% | $18.00 | $39,996 | +38.24% |
Insider Historical Profitability
| Chivukula Pad | Chief Scientific Officer & COO | 447334 1.869% | $24.48 | 0 | 31 | |
| SASSINE ANDY | Chief Financial Officer | 220526 1.0225% | $24.48 | 4 | 1 | +172.25% |
| Kummerfeld Keith C | See Remarks | 950 0.0036% | $24.48 | 2 | 2 | +40.68% |
| Payne Joseph E | President and CEO | 1480097 5.5386% | $24.48 | 3 | 0 | +43.57% |
| Ultragenyx Pharmaceutical Inc. | director | 1400000 5.2389% | $24.48 | 0 | 4 | |
| FARRELL PETER C | director | 42955 0.1607% | $24.48 | 2 | 0 | +21.56% |
| Marquet Magda | director | 24942 0.0933% | $24.48 | 2 | 0 | +34.48% |
Institutional Investor Ownership
| Federated Hermes | $158.56M | 17.43 | 4.7M | -0.34% | -$545,047.80 | 0.37 | |
| BlackRock | $92.63M | 10.19 | 2.74M | +14.37% | +$11.64M | <0.01 | |
| State Street | $66.19M | 7.28 | 1.96M | +20.27% | +$11.15M | <0.01 | |
| ARK Investment Management LLC | $57.06M | 6.27 | 1.69M | -17.48% | -$12.09M | 0.4 | |
| The Vanguard Group | $46.87M | 5.15 | 1.39M | -4.83% | -$2.38M | <0.01 | |
| Nikko Asset Management Americas Inc | $42.98M | 4.74 | 1.28M | -3.34% | -$1.49M | 0.41 | |
| Sumitomo Mitsui Trust Holdings | $43.11M | 4.74 | 1.28M | -3.34% | -$1.49M | 0.03 | |
| Dimensional Fund Advisors | $37.28M | 4.1 | 1.1M | +1.37% | +$502,835.32 | 0.01 | |
| Woodline Partners LP | $30.88M | 3.4 | 914,364 | -14.53% | -$5.25M | 0.29 | |
| Morgan Stanley | $29.33M | 3.23 | 868,447 | +49.22% | +$9.67M | <0.01 | |
| Fidelity Investments | $21M | 2.31 | 621,858 | -28.06% | -$8.19M | <0.01 | |
| Geode Capital Management | $18.59M | 2.04 | 550,263 | +2.23% | +$405,231.45 | <0.01 | |
| Adage Capital Partners Gp L L C | $15.2M | 1.67 | 450,000 | New | +$15.2M | 0.03 | |
| Goldman Sachs | $12.27M | 1.35 | 363,370 | -12.37% | -$1.73M | <0.01 | |
| Jupiter Fund Management | $12.24M | 1.35 | 362,344 | 0% | +$0 | 0.03 | |
| Schonfeld Group | $11.7M | 1.29 | 346,494 | -13.7% | -$1.86M | 0.08 | |
| Granahan Investment Management | $11.35M | 1.25 | 336,147 | -25.36% | -$3.86M | 0.4 | |
| Point72 Asset Management | $11.33M | 1.25 | 335,378 | +1,807.94% | +$10.73M | 0.02 | |
| JPMorgan Chase | $10.72M | 1.18 | 317,551 | -1.63% | -$177,900.36 | <0.01 | |
| Wellington Management Company | $9.63M | 1.06 | 285,115 | +368.62% | +$7.57M | <0.01 | |
| Portolan Capital Management | $8.26M | 0.91 | 244,659 | +67.74% | +$3.34M | 0.63 | |
| Northern Trust | $8M | 0.88 | 236,942 | -4.07% | -$339,624.88 | <0.01 | |
| American Century Investments | $7.83M | 0.86 | 231,745 | +1,353.31% | +$7.29M | 0.01 | |
| Great Lakes Advisors® | $7.1M | 0.78 | 210,391 | +1.58% | +$110,225.28 | 0.06 | |
| Bank of America | $6.71M | 0.74 | 198,557 | +395.61% | +$5.35M | <0.01 | |
| Charles Schwab | $6.44M | 0.71 | 190,766 | +2.39% | +$150,479.12 | <0.01 | |
| Ubs Asset Management Americas Inc | $6.09M | 0.67 | 180,398 | +595.07% | +$5.22M | <0.01 | |
| Citadel Advisors LLC | $5.64M | 0.62 | 167,094 | +45,429.7% | +$5.63M | <0.01 | |
| Millennium Management LLC | $5.35M | 0.59 | 158,519 | +18.6% | +$839,488.49 | <0.01 | |
| Rafferty Asset Management Llc | $5.29M | 0.58 | 156,593 | +38.37% | +$1.47M | 0.02 | |
| Tri Locum Partners Lp | $4.69M | 0.52 | 138,927 | +25.76% | +$960,992.93 | 1.66 | |
| Citigroup | $4.61M | 0.51 | 136,407 | +179.11% | +$2.96M | <0.01 | |
| ROYCE & ASSOCIATES INC | $4.45M | 0.49 | 131,718 | +1.45% | +$63,555.14 | 0.04 | |
| Nuveen | $4.18M | 0.46 | 123,865 | -36.38% | -$2.39M | <0.01 | |
| Arrowstreet Capital, Limited Partnership | $3.94M | 0.43 | 116,797 | +441.33% | +$3.22M | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $3.92M | 0.43 | 115,945 | +16.25% | +$547,175.36 | 0.01 | |
| BNY Mellon | $3.9M | 0.43 | 115,603 | -13.03% | -$584,761.42 | <0.01 | |
| UBS | $3.65M | 0.4 | 107,939 | +48.45% | +$1.19M | <0.01 | |
| Jacobs Levy Equity Management | $3.24M | 0.36 | 95,924 | +111.03% | +$1.7M | 0.02 | |
| Marshall Wace | $2.85M | 0.31 | 84,267 | New | +$2.85M | <0.01 | |
| Neuberger Berman | $2.79M | 0.31 | 82,546 | New | +$2.79M | <0.01 | |
| AQR Capital | $2.51M | 0.28 | 74,225 | -53.57% | -$2.89M | <0.01 | |
| Wells Fargo | $2.42M | 0.27 | 71,658 | -1.8% | -$44,373.79 | <0.01 | |
| Franklin Templeton Investments | $2.39M | 0.26 | 70,646 | +347.18% | +$1.85M | <0.01 | |
| OMERS | $2.13M | 0.23 | 63,000 | 0% | +$0 | 0.02 | |
| Man Group Plc | $2.11M | 0.23 | 62,589 | -27.64% | -$807,575.96 | 0.01 | |
| Nordea Investment Management Ab | $1.85M | 0.21 | 56,931 | New | +$1.85M | <0.01 | |
| State of Wisconsin Investment Board | $1.91M | 0.21 | 56,612 | +65.07% | +$753,644.99 | 0.01 | |
| Assenagon Asset Management S.A. | $1.87M | 0.21 | 55,237 | New | +$1.87M | 0.01 | |
| Quantedge | $1.69M | 0.19 | 50,100 | New | +$1.69M | 0.73 |